Tarek Samad

New Capabilities

Announced THRIVE headline results on October 1, 2026

Migraine patients who try one CGRP-blocking drug and get no relief now have evidence that switching to a different one can work. In Lundbeck's Phase IV THRIVE trial, 60% of participants still in the study after 24 weeks on VYEPTI (eptinezumab) reported being 'much improved' or 'very much improved.'

Updated Oct 20